The Past, Present and Future of Venetoclax Plus Hypomethylating Agent Combination Therapies in AML
出版年份 2021 全文链接
标题
The Past, Present and Future of Venetoclax Plus Hypomethylating Agent Combination Therapies in AML
作者
关键词
Azacitidine, BCL2 and relapsed/refractory, Leukemia stem cells, Targeted therapies
出版物
Clinical Lymphoma Myeloma & Leukemia
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-07-19
DOI
10.1016/j.clml.2021.07.012
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Decitabine and venetoclax for IDH1/2 ‐ mutated acute myeloid leukemia
- (2021) Sangeetha Venugopal et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax
- (2021) Marina Y. Konopleva BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- (2021) Vinod A. Pullarkat et al. Cancer Discovery
- Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
- (2021) Matthew E. Tenold et al. Frontiers in Oncology
- Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
- (2021) Maximilian Stahl et al. Blood Advances
- Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
- (2021) Hareth Nahi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
- (2021) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
- (2021) Rachel Thijssen et al. BLOOD
- Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production
- (2021) JongBok Lee et al. BLOOD
- Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
- (2021) Ralf Buettner et al. Journal of Hematology & Oncology
- Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
- (2021) Curtis A. Lachowiez et al. Blood Advances
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Targeting MCL-1 in hematologic malignancies: Rationale and progress
- (2020) AndrewH. Wei et al. BLOOD REVIEWS
- 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-mediated Apoptosis.
- (2020) Sha Jin et al. CLINICAL CANCER RESEARCH
- Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
- (2020) Daria Gaut et al. LEUKEMIA RESEARCH
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients
- (2020) Shanshan Pei et al. Cancer Discovery
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells
- (2020) Courtney L. Jones et al. Cell Stem Cell
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
- (2020) Shruti Bhatt et al. CANCER CELL
- Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax
- (2020) Mario L. Marques-Piubelli et al. LEUKEMIA & LYMPHOMA
- The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
- (2019) Le Xuan Truong Nguyen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity
- (2019) Kevin H. Lin et al. Cell Metabolism
- Venetoclax-based Therapies for Acute Myeloid Leukemia
- (2019) Veronica A. Guerra et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
- (2019) Lina Han et al. HAEMATOLOGICA
- Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
- (2019) Xufeng Chen et al. Cancer Discovery
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
- (2019) Ron Ram et al. ANNALS OF HEMATOLOGY
- Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
- (2019) Heikki Kuusanmäki et al. HAEMATOLOGICA
- Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
- (2019) Felix Seyfried et al. Cell Death & Disease
- Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response
- (2019) David Sharon et al. Science Translational Medicine
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- BCL-2 inhibition in AML: an unexpected bonus?
- (2018) Marina Konopleva et al. BLOOD
- Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1
- (2018) Daniel A. Luedtke et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia
- (2018) Haley E. Ramsey et al. Cancer Discovery
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
- (2018) Courtney L. Jones et al. CANCER CELL
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Tracing the origins of relapse in acute myeloid leukaemia to stem cells
- (2017) Liran I. Shlush et al. NATURE
- Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
- (2017) Joel D. Leverson et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
- (2016) Kevin H. Lin et al. Scientific Reports
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
- (2015) Jo Ishizawa et al. PLoS One
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
- (2010) H. Kantarjian et al. BLOOD
- A comparison of gene expression profiles between primary human AML cells and AML cell line
- (2008) Jinseok Lee et al. GENES & GENETIC SYSTEMS
- Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia
- (2008) J A Kennedy et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now